Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176486 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02176486 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 12 participants.
The verdict
NCT02176486, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
Interventions
- DRUG Placebo
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-06-09 |
| Est. Completion | 2018-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02176486
The ClinicalTrials.gov registry entry for NCT02176486 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02176486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02176486 about?
NCT02176486 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)". The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
What is the current status of trial NCT02176486?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-06-09. Estimated completion is 2018-01-19.
What interventions are being tested in trial NCT02176486?
The interventions under investigation include: Placebo (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02176486?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.